Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms

Journal of Antimicrobial Chemotherapy

Volumn 49, Issue 6, 2002, Pages 973-980

  Ramage, Gordon ^a   Bachmann, Stefano ^b   Patterson, Thomas F ^b   Wickes, Brian L ^a   López Ribot, José L ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Biofilm; Candida albicans; Efflux pumps; Resistance

Indexed keywords

ABC TRANSPORTER; ANTIFUNGAL AGENT; FLUCONAZOLE; MULTIDRUG RESISTANCE PROTEIN; PYRROLE; FUNGAL PROTEIN; GLYCOPROTEIN P;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BIOFILM; CANDIDA ALBICANS; CELL MUTANT; CONTROLLED STUDY; DRUG MECHANISM; EFFUSION; EXTRACELLULAR MATRIX; FUNGUS GROWTH; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENETIC CODE; MULTIDRUG RESISTANCE; NONHUMAN; NORTHERN BLOTTING; PHENOTYPE; PLANKTON; STRAIN DIFFERENCE; YEAST CELL; ACTIVE TRANSPORT; ANTIBIOTIC RESISTANCE; DRUG EFFECT; GENETICS; GROWTH, DEVELOPMENT AND AGING; MUTATION; PHYSIOLOGY;

BIOFILMS; BIOLOGICAL TRANSPORT, ACTIVE; CANDIDA ALBICANS; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; FUNGAL PROTEINS; MUTATION; P-GLYCOPROTEINS;

EID: 0035992139     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkf049     Document Type: Article

References (37)

1. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System
2. National surveillance of nosocomial blood stream infection due to Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE Program
3. Intravascular catheter-associated infections
4. Candida biofilms and their susceptibility to antifungal agents
5. Forging a link between biofilms and disease
6. Expression of the multiple antibiotic resistance operon (mar) during growth of Escherichia coli as a biofilm
7. Biofilm susceptibility to antimicrobials
8. Establishment of aging biofilms: Possible mechanism of bacterial resistance to antimicrobial therapy
9. Effect of growth rate on resistance of Candida albicans biofilms to antifungal agents
10. Matrix polymers of Candida biofilms and their possible role in biofilm resistance to anti-fungal agents
11. Antifungal resistance of candidal biofilms formed on denture acrylic in vitro
12. Resistance of Candida albicans biofilms to antifungal agents in vitro
13. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms
14. Characteristics of biofilm formation by Candida albicans
15. Bacterial resistance to antibiotics: The role of biofilms
16. Susceptibility of bacterial biofilms to tobramycin: Role of specific growth rate and phase in the division cycle
17. Multidrug efflux pumps: Expression patterns and contribution to antibiotic resistance in Pseudomonas aeruginosa biofilms
18. Riddle of biofilm resistance
19. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance
20. Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus-infected patients
21. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: Characterization of CDR2, a new multidrug ABC transporter gene
22. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance
23. Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and anti-fungals
24. New evidence that Candida albicans possesses additional ATP-binding cassette MDR-like genes: Implications for antifungal azole resistance
25. ABC transporters: From microorganisms to man
26. Yeast multidrug resistance: The PDR network
27. Analysis of a Candida albicans gene that encodes a novel mechanism for resistance to benomyl and methotrexate
28. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus
29. Innovative endpoint determination system for antifungal susceptibility testing of yeasts
30. Comparison of a 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[ (phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) colorimetric method with the standardized National Committee for Clinical Laboratory clinical yeast isolates for susceptibility to antifungal agents
31. Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard M27-A
32. Distinct patterns of gene expression associated with development of fluconazole resistance in serial Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis
33. Production of extracellular matrix by Candida albicans biofilms
34. The glycocalyx, biofilm, microbes, and resistant infection
35. Major facilitator superfamily
36. Fungal transporters involved in efflux of natural toxic compounds and fungicides
37. A major superfamily of transmembrane facilitators that catalyse uniport, symport and antiport